No. 364-Antenatal Corticosteroid Therapy for Improving Neonatal Outcomes

Skoll, Amanda; Boutin, Amélie; Bujold, Emmanuel; Burrows, Jason; Crane, Joan; Geary, Michael; Jain, Venu; Lacaze‐Masmonteil, Thierry; Liauw, Jessica; Mundle, William; Murphy, Kellie; Wong, Suzanne; Joseph, K.S.

doi:10.1016/j.jogc.2018.04.018

Cited by 105 publications

(86 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The American College of Obstetricians and Gynecologists recommends a single course of betamethasone for pregnant women between 34 (0/7) to 36 (6/7) weeks of gestation, and at risk of giving birth within 7 days, who had not received a prior course of ACS treatment [23]. The Society of Obstetricians and Gynecologists of Canada suggests that possible neonatal benefit should be weighed against possible long-term harm when considering ACS at 35 to 36 weeks gestation [24]. In this cohort study, we nd maternal ACS is related to decreasing the incidence of NRDS, length of neonatal hospital stay, and neonatal hospital expenses.…”

Section: Discussionmentioning

confidence: 99%

Short term outcomes of preterm infants following antenatal corticosteroid treatment for childbearing women at 34 (0/7) to 36 (6/7) weeks: do the advantages outweigh the disadvantages?

Deng

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background The effects of maternal antenatal corticosteroid (ACS) treatment, for fetal maturation, on the short-term outcome of late preterm infants are unclear. Methods This is a retrospective cohort study conducted in the Second Affiliated Hospital of Shantou University Medical College. Data of pregnant women who gave birth between 34 (0/7) to 36 (6/7) weeks gestation from January 2014 to June 2019 were collected. Nine short-term outcomes of preterm infants from mothers who received ACS treatment were compared to preterm infants from mothers who did not receive ACS treatment. Results In total, 1393 pregnant women (of whom 757 accepted ACS treatment before delivery) and 1472 preterm infants were eligible for analysis. The results were as follows: (1) ACS administration to pregnant women at high risk for giving birth between 34 (0/7) to 36 (6/7) weeks pregnancy , was related to decreasing cost and infant inpatient time (slope was -0.784, P =0.026 and slope was -933.173, P =0.001, respectively); (2) lack of maternal ACS treatment was an independent risk factor for neonatal respiratory distress syndrome (RR=0.548, 95%CI=0.332～0.906); (3) use of maternal ACS did not increase risk of neonatal pneumonia, neonatal hypoglycemia, neonatal sepsis, necrotizing enterocolitis of newborns, neonatal intracranial hemorrhage, and hypoxic-ischemic encephalopathy in preterm infants. Conclusions Use of ACS for pregnant women at risk for giving birth between 34 (0/7) to 36 (6/7) weeks pregnancy may have more advantages than disadvantages. Our study provides evidence-based medicine for clinicians to make ACS treatment choices for pregnant women with risk of giving birth between 34 (0/7) to 36(6/7) weeks gestation.

show abstract

Section: Discussionmentioning

confidence: 99%

Short term outcomes of preterm infants following antenatal corticosteroid treatment for childbearing women at 34 (0/7) to 36 (6/7) weeks: do the advantages outweigh the disadvantages?

Deng

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The American College of Obstetricians and Gynecologists recommends a single course of betamethasone for pregnant women between 34 (0/7) to 36 (6/7) weeks of gestation, and at risk of giving birth within 7 days, who had not received a previous course of ACS treatment [23]. The Society of Obstetricians and Gynecologists of Canada suggests that possible neonatal bene t should be weighed against possible long-term harm when considering ACS at 35 to 36 weeks gestation [24]. In this cohort study, we found maternal ACS can decrease the incidence of NRDS, length of neonatal hospital stay, and neonatal hospital expenses.…”

Section: Discussionmentioning

confidence: 99%

Short term outcomes of preterm infants following antenatal corticosteroid treatment for childbearing women at 34 (0/7) to 36 (6/7) weeks: do the advantages outweigh the disadvantages?

Deng

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background The effects of maternal antenatal corticosteroid (ACS) treatment on the short-term outcome of late preterm infants are unclear.Methods This is a retrospective cohort study. Data of pregnant women who gave birth between 34 (0/7) to 36 (6/7) weeks gestation from January 2014 to June 2019 were collected. Nine short-term outcomes of preterm infants from mothers who received ACS treatment were compared to preterm infants from mothers who did not receive ACS treatment.Results The results were as follows: (1) ACS administration to pregnant women at high risk for giving birth between 34 (0/7) to 36 (6/7) weeks pregnancy, can decrease the cost and inpatient time of their infants; (2) lack of maternal ACS treatment is an independent risk factor for neonatal respiratory distress syndrome; (3) use of maternal ACS does not increase the risk of neonatal pneumonia, neonatal hypoglycemia, neonatal sepsis, necrotizing enterocolitis of newborns, neonatal intracranial hemorrhage, and hypoxic-ischemic encephalopathy in preterm infants.Conclusions Use of ACS for pregnant women at risk for giving birth between 34 (0/7) to 36 (6/7) weeks pregnancy has more advantage than disadvantage. Our study provides evidence-based medicine for clinicians to make ACS treatment choices for pregnant women with risk of giving birth between 34 (0/7) to 36(6/7) weeks gestation.

show abstract

“…Current antenatal steroid administration is conducted by two different protocols, and dexamethasone and betamethasone are used for this purpose. [2] The effects of two different molecules on lung maturation and intraventricular hemorrhage rate are similar. While dexamethasone is a molecule which is cheap and easy to obtain, the binding rate of betamethasone to albumin is lower and this increases the transplacental transition rate.…”

Section: Dear Editormentioning

confidence: 98%

Letter to the Editor: Antenatal steroids and their administration time for preventing morbidity in preterm labor

Dilek¹,

Aydeniz²

2018

Perinatal J

View full text Add to dashboard Cite

No. 364-Antenatal Corticosteroid Therapy for Improving Neonatal Outcomes

Cited by 105 publications

References 94 publications

Short term outcomes of preterm infants following antenatal corticosteroid treatment for childbearing women at 34 (0/7) to 36 (6/7) weeks: do the advantages outweigh the disadvantages?

Short term outcomes of preterm infants following antenatal corticosteroid treatment for childbearing women at 34 (0/7) to 36 (6/7) weeks: do the advantages outweigh the disadvantages?

Short term outcomes of preterm infants following antenatal corticosteroid treatment for childbearing women at 34 (0/7) to 36 (6/7) weeks: do the advantages outweigh the disadvantages?

Letter to the Editor: Antenatal steroids and their administration time for preventing morbidity in preterm labor

Contact Info

Product

Resources

About